<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.0" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">SMF</journal-id>
      <journal-title-group>
        <journal-title>Schweizerisches Medizin-Forum</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1424-4020</issn>
      <issn pub-type="ppub">1424-3784</issn>
      <publisher>
        <publisher-name>EMH Schweizerischer Ärzteverlag AG</publisher-name>
        <publisher-loc>Farnsburgerstrasse 8
CH-4132 Muttenz</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">08619</article-id>
      <article-id pub-id-type="doi">10.4414/smf.2021.08619</article-id>
      <article-categories>
        <!-- rubric -->
        <subj-group subj-group-type="Article Type">
          <subject>Übersichtsartikel</subject>
        </subj-group>
        <!-- topics -->
        <subj-group subj-group-type="Classification">
          <subject>Allergologie / Immunologie</subject>
          <subject>Dermatologie und Venerologie</subject>
          <subject>Klinische Pharmakologie und Toxikologie</subject>
          <subject>Oto-Rhino-Laryngologie</subject>
          <subject>Pneumologie</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>TH2-Immunantwort: Bedeutung und therapeutische Beeinflussung</article-title>
      </title-group>
      <contrib-group>
        <contrib id="author-1" contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Kühn</surname>
            <given-names>Marcus</given-names>
          </name>
          <email>Marcus.Kuehn@usz.ch</email>
          <aff/>
        </contrib>
        <contrib id="author-2" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Dimitriou</surname>
            <given-names>Florentia</given-names>
          </name>
          <email>Florentia.dimitriou@usz.ch</email>
          <aff>Klinik für Immunologie, UniversitätsSpital Zürich</aff>
        </contrib>
        <contrib id="author-3" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Steiner</surname>
            <given-names>Urs C.</given-names>
          </name>
          <email>Urs.Steiner@usz.ch</email>
          <aff>UniversitatsSpital Zurich | Clinical Immunology | Gloriastrasse 23 | Zurich | 8091 | SWITZERLAND</aff>
        </contrib>
      </contrib-group>
      <pub-date pub-type="epub" date-type="pub" iso-8601-date="2021.01.05">
        <day>05</day>
        <month>01</month>
        <year>2021</year>
      </pub-date>
      <volume>21</volume>
      <issue>0102</issue>
      <fpage>13</fpage>
      <lpage>17</lpage>
      <permissions>
        <copyright-statement>Copyright: EMH Schweizerischer Ärzteverlag AG</copyright-statement>
        <copyright-year>2021</copyright-year>
        <copyright-holder>EMH Schweizerischer Ärzteverlag AG</copyright-holder>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
          <license-p>"Swiss Medical Forum" is an open access publication of EMH published in accordance with the terms of the Creative Commons licence attribution - NonCommercial - NoDerivatives 4.0 International. You are free to share, copy and redistribute the material in any medium or format under the following terms:</license-p>
          <license-p>Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.</license-p>
          <license-p>NonCommercial — You may not use the material for commercial purposes.</license-p>
          <license-p>NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.</license-p>
          <license-p>"Non-commercial" means not primarily intended for or directed towards commercial advantage or monetary compensation. The incorporation of publications in commercial products, the use of publications to advertise for commercial products or services and any other usage that directly or indirectly pursues commercial interests is subject to the express previous consent of the publishing house as part of a written agreement.</license-p>
          <license-p>Please send us your request in writing. Exact indication of the publication from which you would like to reproduce material and detailed information about its intended use help to facilitate and expedite request processing.</license-p>
        </license>
      </permissions>
      <abstract abstract-type="article" xml:lang="de">
        <p>Das Immunsystem schützt uns vor Krankheitserregern und Fremdkörpern. Je nach Pathogen und zusätzlichen Einflüssen kann die Immunreaktion unterschiedlich verlaufen. Klassischerweise unterscheiden wir eine TH-1 Immunantwort bei bakteriellen und viralen Infektionen von einer TH-2 Immunantwort, die typischerweise bei allergischen Reaktionen auftritt. Sie unterscheiden sich durch ihr charakteristisches Zytokinmilieu mit Entwicklung spezifischer Zellen und Antikörper. In den letzten Jahren wurden neuartige Medikamente, sogenannte Biologika, entwickelt, die gezielt Zytokine und Rezeptoren auf Zellen erkennen und so das Immunsystem beeinflussen. Wir gehen im folgenden Artikel näher auf die TH-2 Immunantwort mit ihren klinischen Manifestationen ein und beleuchten die aktuellen therapeutischen Möglichkeiten und Entwicklungen betreffend Biologika.</p>
      </abstract>
    </article-meta>
  </front>
  <body/>
  <back/>
</article>
